

The LMU Munich Hospital is one of the top national centers involved in the care of cancer patients. The various oncology disciplines are bundled in the Comprehensive Cancer Center CCC^{LMU} (<https://www.lmu-klinikum.de/ccc>)

The Interdisciplinary Center for Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET) at the LMU Hospital Munich is one of the approved centers of the Comprehensive Cancer Center CCC^{LMU} (<https://www.lmu-klinikum.de/ccc>) and has been certified by the European Neuroendocrine Tumor Society (ENETS) as a Center of Excellence (<https://www.enets.org/coe.html>).

The Interdisciplinary Center for Neuroendocrine Tumors of the Gastroenteropancreatic System (GEPNET Center) at the LMU Hospital Munich is a center that aims to provide optimised interdisciplinary medical care of the highest standard for patients with neuroendocrine tumors of the gastroenteropancreatic system. Treatment planning is carried out by the Interdisciplinary Tumor Board for Neuroendocrine Tumors. In addition to the „state of the art“ in diagnostics and therapy, it also offers the latest innovative and recent diagnostic and therapeutic options from various specialised disciplines so that translational knowledge and clinical research can be used to the benefit of patients.

The following tumor entities are treated at the GEPNET Center:

Neuroendocrine Tumors derived from the gastroenteropancreatic system. Primary tumor location can be found in the small intestine (jejunum/ileum), the pancreas, the appendix, the colon, the stomach, the duodenum or the rectum. Frequently diagnosis is established by liver metastasis; the primary tumor is sometimes unknown (cancer of unknown primary, CUP).

The following tumor entities belong to the neuroendocrine neoplasias / neuroendocrine tumors:

- Neuroendocrine Tumor
- Neuroendocrine Carcinoma
- Carcinoid
- MANEC / MINEN
- Functionally active neuroendocrine tumors, with clinical syndromes, e.g.:
 - Carcinoid-Syndrom
 - Insulinoma
 - Gastrinoma (Zollinger-Ellison-Syndrome)
 - VIPoma (Werner-Morrison-Syndrome)
 - Glucagonoma

Familial tumor syndromes with genetic background for neuroendocrine tumors, e.g.:

- Multiple Endocrine Neoplasia Type 1 (MEN 1)
- Von-Hippel-Lindau Syndrome (VHL)

All international established procedures for the diagnosis and treatment of neuroendocrine tumors are provided at the GEPNET Center:

Examples of diagnostic procedures at the GEPNET Center:

- ⁶⁸Ga-DOTATATE-PET/CT / ¹⁸F-SiFalin-TATE-PET/CT
- ¹⁸F-FDG-PET/CT
- [⁶⁸Ga]Ga-exendin-4-PET/CT
- MRI protocols optimized for GEPNET diagnostic
- CT protocols optimized for GEPNET diagnostic
- contrast enhanced ultrasound sonography (CEUS)
- Endoscopy
- Endosonography (EUS) and EUS-guided biopsy
- Sonography- or CT-guided biopsy
- Endocrine testing
- Genetic counseling and diagnostic

Examples of therapeutic procedures at the GEPNET Center:

- Endoscopy – mucosal resection (EMR) / submucosal dissection (ESD) / full-thickness resection (EFTR)
- Visceral surgery – all established laparoscopic and open surgical procedures, hepatobiliary surgery, intestinal surgery, pancreatic surgery, oncological surgery
- Interventional therapies – brachytherapy, radiofrequency ablation (RFA), transarterial embolisation and chemoembolisation (TAE and TACE)
- Nuclear medicine - Peptid-based Radio Receptor Therapy (PRRT) with e.g. ¹⁷⁷Lutetium-DOTA-TATE and Selective Intra-arterial Radiotherapy (SIRT) with e.g. ⁹⁰Yttrium-Mikrobeads
- Oncology – biotherapy, chemotherapy, molecular targeted therapy
- Personalised medicine / Molecular pathology / Molecular tumorboard
- External radiation
- Supportive therapies – nutrition, pain therapy, palliative therapy, psychooncology